CA2005704A1 - Pneumolysin mutants and pneumococcal vaccines made therefrom - Google Patents

Pneumolysin mutants and pneumococcal vaccines made therefrom

Info

Publication number
CA2005704A1
CA2005704A1 CA002005704A CA2005704A CA2005704A1 CA 2005704 A1 CA2005704 A1 CA 2005704A1 CA 002005704 A CA002005704 A CA 002005704A CA 2005704 A CA2005704 A CA 2005704A CA 2005704 A1 CA2005704 A1 CA 2005704A1
Authority
CA
Canada
Prior art keywords
mutants
made therefrom
pneumolysin
pneumococcal vaccines
vaccines made
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002005704A
Other languages
French (fr)
Other versions
CA2005704C (en
Inventor
James C. Paton
David J. Hansman
Graham J. Boulnois
Peter W. Andrew
Timothy J. Mitchell
John A. Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlanden Welzijn Volksgezondheid en Cultuur Minister van
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2005704A1 publication Critical patent/CA2005704A1/en
Application granted granted Critical
Publication of CA2005704C publication Critical patent/CA2005704C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Current-Collector Devices For Electrically Propelled Vehicles (AREA)

Abstract

Mutants of pneumolysin that are non-toxic by reason of amino acid substitutions have been constructed. These mutants elicit an immune response in animals that is reactive to wild-type pneumolysin. The invention also encompasses vaccines for humans based on these mutants, including vaccines comprising conjugates with pneumococcal capsular polysaccharides.
CA002005704A 1988-12-16 1989-12-15 Pneumolysin mutants and pneumococcal vaccines made therefrom Expired - Lifetime CA2005704C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPJ1989 1988-12-16
AUPJ198988 1988-12-16

Publications (2)

Publication Number Publication Date
CA2005704A1 true CA2005704A1 (en) 1990-06-16
CA2005704C CA2005704C (en) 2003-02-11

Family

ID=3773589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002005704A Expired - Lifetime CA2005704C (en) 1988-12-16 1989-12-15 Pneumolysin mutants and pneumococcal vaccines made therefrom

Country Status (15)

Country Link
EP (1) EP0449856B1 (en)
JP (1) JP3237842B2 (en)
AT (1) ATE205534T1 (en)
AU (1) AU626961B2 (en)
BG (1) BG51358A3 (en)
CA (1) CA2005704C (en)
DE (1) DE68929323T2 (en)
DK (1) DK173629B1 (en)
ES (1) ES2160570T3 (en)
FI (1) FI103122B1 (en)
HU (1) HUT58804A (en)
MC (1) MC2178A1 (en)
NO (1) NO304317B1 (en)
RU (1) RU2121481C1 (en)
WO (1) WO1990006951A1 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716432B1 (en) * 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5391712A (en) * 1991-08-30 1995-02-21 Beckman Instruments, Inc. Non-hemolytic streptolysin O variants
US5928900A (en) * 1993-09-01 1999-07-27 The Rockefeller University Bacterial exported proteins and acellular vaccines based thereon
EP0687688A1 (en) * 1993-12-17 1995-12-20 Universidad De Oviedo Antibodies against pneumolysine and their applications
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
EP0998557A2 (en) * 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
BRPI0009163B8 (en) * 1999-03-19 2021-05-25 Glaxosmithkline Biologicals Sa immunogenic composition and vaccine comprising it
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2189473A3 (en) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nucleic and proteins from streptococcus groups A & B
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
WO2004014417A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
AU2003278166B2 (en) 2002-11-01 2009-01-29 Glaxosmithkline Biologicals S.A. Immunogenic composition
KR20050086427A (en) * 2002-11-07 2005-08-30 시너지 아메리카 인코포레이티드 Compositions and methods for treating or preventing pneumococcal infection
DK1601689T3 (en) 2003-03-13 2008-03-25 Glaxosmithkline Biolog Sa Bacterial cytolysin purification procedure
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1667712B1 (en) 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. B. pertussis antigens and use thereof in vaccination
EP1713917A4 (en) * 2004-02-13 2009-06-17 Sanofi Pasteur Ltd Pneumolysin derivatives
WO2005108419A1 (en) * 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
JP2008508320A (en) 2004-07-29 2008-03-21 カイロン コーポレイション Immunogenic composition against gram positive bacteria such as STREPTOCOCCUSAGALACTIAE
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
WO2006042027A2 (en) 2004-10-08 2006-04-20 Novartis Vaccines And Diagnostics Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP1973564B1 (en) 2005-12-22 2016-11-09 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
NZ569417A (en) 2006-01-17 2012-04-27 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
ES2657392T3 (en) 2006-09-26 2018-03-05 Infectious Disease Research Institute Vaccine composition containing a synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2433648A3 (en) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
WO2008043774A1 (en) 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
CN101675068A (en) 2007-03-02 2010-03-17 葛兰素史密丝克莱恩生物有限公司 Novel method and compositions
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
WO2009023300A2 (en) 2007-04-13 2009-02-19 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
US20100183662A1 (en) 2007-06-26 2010-07-22 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
JP5653215B2 (en) 2007-09-12 2015-01-14 ノバルティス アーゲー GAS57 mutant antigen and GAS57 antibody
KR20160114196A (en) 2007-12-21 2016-10-04 노파르티스 아게 Mutant forms of streptolysin o
PT2271360E (en) 2008-04-16 2015-12-07 Glaxosmithkline Biolog Sa Vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
CN106008679A (en) * 2008-12-24 2016-10-12 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 Modified Steptococcus pneumonia pneumolysin (PLY) polypeptides
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
PT2437753T (en) 2009-06-05 2016-11-23 Infectious Disease Res Inst Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
WO2011075822A1 (en) 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions and related methods
JP5894083B2 (en) * 2009-12-22 2016-03-23 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ Immunogenic composition
EP2544693B1 (en) 2010-03-09 2017-09-13 Biomedical Research Models, Inc. A novel mucosal vaccination approach for herpes simplex virus type-2
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011110636A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition
KR101958753B1 (en) 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. Antibodies that bind human cd27 and uses thereof
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
MX350795B (en) 2011-04-08 2017-09-19 Inmune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses.
AU2012257771C1 (en) 2011-05-17 2015-12-03 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
LT2811981T (en) 2012-02-07 2019-06-10 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
LT2850431T (en) 2012-05-16 2018-06-25 Immune Design Corp. Vaccines for hsv-2
WO2014107731A1 (en) 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
JP6426706B2 (en) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション GLA monotherapy for use in cancer treatment
US11207396B2 (en) 2013-05-17 2021-12-28 The Board Of Regents Of The University Of Texas System Immunization to protect against adverse cardiac events relating to pneumococcal infection
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
KR102411781B1 (en) 2013-12-31 2022-06-22 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Single vial vaccine formulations
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
KR102304828B1 (en) 2014-11-21 2021-09-27 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 Pneumolysin mutants and methods of use thereof
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
MA44723A (en) 2016-04-18 2019-02-27 Celldex Therapeutics Inc HUMAN CD40 BINDING AGONIST ANTIBODIES AND THEIR USES
JP7195147B2 (en) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート PEGylated liposomes and methods of use
DK3458475T3 (en) 2016-05-16 2022-09-12 Access To Advanced Health Inst FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE
IL298227B2 (en) 2016-06-01 2024-09-01 Access To Advanced Health Inst Nanoalum particles containing a sizing agent
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
JP2020524143A (en) 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート Nanostructured lipid carriers, stable emulsions, and uses thereof
EP3678695A1 (en) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
EP3781265A2 (en) 2018-04-17 2021-02-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
US20220016168A1 (en) 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
JP2022532944A (en) 2019-05-25 2022-07-20 アクセス ツー アドバンスト ヘルス インスティチュート Compositions and Methods for Spray Drying of adjuvant Vaccine Emulsions
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
EP3919076A1 (en) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
EP4320159A1 (en) 2021-04-09 2024-02-14 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
EP4433080A1 (en) 2021-11-18 2024-09-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Also Published As

Publication number Publication date
EP0449856A4 (en) 1992-05-20
FI103122B (en) 1999-04-30
WO1990006951A1 (en) 1990-06-28
JPH04503948A (en) 1992-07-16
AU4756490A (en) 1990-07-10
EP0449856A1 (en) 1991-10-09
FI103122B1 (en) 1999-04-30
MC2178A1 (en) 1992-05-22
DK115591A (en) 1991-08-14
BG51358A3 (en) 1993-04-15
FI912878A0 (en) 1991-06-14
DE68929323D1 (en) 2001-10-18
JP3237842B2 (en) 2001-12-10
NO912226D0 (en) 1991-06-11
EP0449856B1 (en) 2001-09-12
ES2160570T3 (en) 2001-11-16
CA2005704C (en) 2003-02-11
ATE205534T1 (en) 2001-09-15
DE68929323T2 (en) 2002-04-18
AU626961B2 (en) 1992-08-13
NO304317B1 (en) 1998-11-30
NO912226L (en) 1991-07-25
RU2121481C1 (en) 1998-11-10
DK173629B1 (en) 2001-05-14
DK115591D0 (en) 1991-06-14
HUT58804A (en) 1992-03-30

Similar Documents

Publication Publication Date Title
CA2005704A1 (en) Pneumolysin mutants and pneumococcal vaccines made therefrom
WO1999003884A3 (en) Modified immunogenic pneumolysin, compositions and their use as vaccines
EP0370573A3 (en) Skin test and test kit for aids
IL115047A (en) Immunogenic conjugates comprising pneumococcal polysaccharide and recombinant pneumolysin, vaccines comprising such conjugates and use of such vaccines in the manufacture of medicaments for immunizing against pneumococcal infections
ZA837603B (en) Immunogenic protein or peptide complex,method of producing said complex and the use thereof as an immune stimulant and as a vaccine
ZA956412B (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
NZ239878A (en) Oligosaccharide-carrier protein conjugate and its production
EP0024493A3 (en) Pneumococcal capsular polysaccharide, preparation thereof, multivalent pneumococcal vaccine and method of inducing active immunity
GB9626484D0 (en) Helicobacter pylori antigenic protein preparation and immunoassays
IE801902L (en) Copolymer
CA2059692A1 (en) Pneumoccoccal polysaccharide conjugate vaccine
ZA852724B (en) Multivalent pneumococcal vaccine and preparation thereof
EA199700419A1 (en) VACCINE COMPOSITION CONTAINING POLYRIBOSILRIBITOLPHOSPHATE AND METHOD FOR ITS PREPARATION
GB2234436B (en) Fish vaccine comprising an avirulent, invasive bacterium
HUP9801223A2 (en) Method for enhancing the antibody response to specific antigens with interleukin-10
EP0338265A3 (en) Haemophilus influenzae type b polysaccharide-outer membrane protein conjugate vaccine
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
CA2273922A1 (en) Novel saponin compositions and uses thereof
Fabio Immunological studies of ginseng
Rethy Jr et al. The purification-method-dependent immunogenicity of diphtheria toxoid. II. The human immunogenicity of differently purified toxoids.
Paton Pathogenesis of pneumococcal disease
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen
PART et al. Moscow ZTIURNAL MIKROBIOLOGX1 EPIDEMTOLOGTI I TMMUNOBIOLOGT1 in Russian No 12, Dec 84 (manuscript received 6 Feb 84) pp 110-113 PETROV, R. 7., KHAITOV, R. M, SEMENOV, BE, ALEKSEYEVA, N. Yu., NEKRASOV, AV, APARIN, PG and VANEYEVA, NP, Institute of Immunology, USSR Ministry of Health; Central Scientific Research Institute of Vaccines
Molina-de-Orozco Albumin and insulin conjugates of a-glucosidases: preparation and kinetic characterization
Khashimova et al. Studies of Listeria antigens and protein fractions isolated from them.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry